This is the past and present work done in the Meyer Lab.

1)  Hematopoietic graft engineering to prevent GVHD and promote healthy immune reconstitution / graft versus leukemia effects. We are conducting a phase 2 trial sorting donor Tregs and hematopoietic cells for transplantation that is almost completed (BMT 236). We are supporting graft engineering trials of a Stanford cell therapy startup called OrcaTherapeutics.  JCI Insight 2019

2) GVHD treatment trials. We are participating and conducting industry and consortium trials to treat GVHD. We are conducting a phase 1 trial to treat GVHD with T regulatory cells and in the process of developing genetically modified T regulatory cells to treat GVHD. 

3) Hematopoietic mixed chimerism and Tregulatory cell therapy to promote kidney allograft immune tolerance. We are involved in ongoing CIRM and NIH supported clinical trials using combined kidney and allogeneic hematopoietic stem cell transplantation to induce tolerance. This includes a phase 1 trial in conjunction with Northwestern University that incorporates T regulatory cells into this strategy to promote donor engraftment.  Science translational, in press.

4) Islet transplantation. We are involved in phase 1 clinical trial efforts to improve human clinical islet transplantation using T regulatory cells and combined islet and hematopoietic stem cell transplantation.  JCI insight 2017

1)  Development and understanding of genetically modified Tregulatory cells for transplantation. JCI Insight 2017

2) Assessment of human immune reconstitution after allogeneic transplantation. Blood 2019, in press.

3) The biology of TIM-1 in transplantation tolerance. Blood Advances 2019

3) Investigating the pathophysiology of iNKT, Tregulatory and myeloid APC in transplantation and T1D.  Blood 2019, in press.